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Background: Somatic gain-of-function mutations in EGFR (exons 19 
and 21) and KRAS, (exon 2) are found in some lung adenocarcinomas. 
In patients with metastatic disease, these mutations have predictive and 
prognostic signiﬁcance: 1) EGFR mutations are associated with sensi-
tivity to the tyrosine kinase inhibitors, geﬁtinib and erlotinib, 2) KRAS 
mutations are associated with primary resistance to these drugs, and 3) 
patients with EGFR mutant tumors may have a longer overall survival 
(OS) versus patients with EGFR wildtype tumors. Whether EGFR and 
KRAS mutations also have an impact on survival, when compared to 
one another, in patients who undergo lung resection for curative intent 
in the absence of targeted therapy has not been established.
Methods: We analyzed the clinical characteristics and outcomes data 
for 300 patients who underwent resection at our institution for Stage 
I-III lung adenocarcinoma. Tumors from all patients were assessed for 
both EGFR and KRAS mutations by direct dideoxynucleotide sequenc-
ing by the Genome Sequencing Center at Washington University St. 
Louis, and/or PCR based methods at Memorial Sloan-Kettering Cancer 
Center. Survival distributions were estimated using Kaplan-Meier 
curves and compared using the log-rank test. 
Results: We found EGFR and KRAS mutations in tumors from 40 and 
50 patients, respectively. No tumor had both mutations. None of the 
patients with mutations received induction or adjuvant therapy with 
erlotinib or geﬁtinib. With a median time to follow-up of 22.3 months, 
patients with EGFR mutant tumors had a longer overall survival on 
univariate analysis versus patients with KRAS mutant tumors (p=0.015, 
see Figure 1) and a trend towards longer survival versus patients with 
tumors wildtype for both genes (p=.070). After adjustment for patho-
logic stage, patients with EGFR mutations displayed a trend towards 
longer survival when compared to patients with KRAS mutations 
(p=0.166). The median OS for patients with EGFR mutant or wildtype 
tumors was not reached, while for the patients with KRAS 
Conclusions: In the absence of treatment with EGFR-targeted therapy, 
EGFR and KRAS mutations are positive and negative molecular predic-
tors, respectively, of survival in resected lung adenocarcinoma. These 
data suggest further that EGFR and KRAS mutations deﬁne clinically 
distinct molecular subsets of lung adenocarcinoma. Mutational status 
should be routinely performed on resected specimens, and EGFR and 
KRAS mutations should be considered as prognostic factors in studies 
of adjuvant therapy.
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Background: NSCLC is one of the leading causes of cancer-related 
deaths; however, a substantial number of patients with early stage dis-
ease will survive after treatment. No comprehensive clinical programs 
designed for NSCLC survivors exist and few studies examine the clini-
cal characteristics and quality of life in NSCLC survivors. 
Methods: A novel thoracic cancer survivorship program (TCSP) 
utilizing a nurse practitioner (NP) care model was developed at a single 
institution. Eligible patients include those with history of Stage I/II 
NSCLC, 1 year after surgical resection without evidence of disease. 
Cancer surveillance and post-treatment evaluation are performed by 
the NP with history and physical examination and a contrast-enhanced 
chest CT scan biannually for the second post-operative year and an-
nually thereafter. Patient demographics, clinical characteristics, QOL 
assessment and cancer screening compliance data are collected in a 
prospective thoracic survivorship database. Retrospective review to 
examine baseline clinical characteristics and QOL was performed.
Results: A total of 223 patients with NSCLC were seen in the TCSP 
from January, 2006 through February, 2007. The mean age was 71 
years (range 48-91). Fifty-eight percent (n=129) were female. Eighty-
ﬁve percent (n=191) of patients were diagnosed with Stage I NSCLC, 
and 87% (n=195) were treated with surgery alone. A small number of 
patients received either induction (n=14, 6%) or adjuvant treatment 
(n=14, 6%) with either chemotherapy, radiation therapy, or both. Dis-
ease-free interval ranged from 1-18 years. Eighty-one percent (n=181) 
of patients identiﬁed themselves as former tobacco smokers, with only 
5% (n=11) reporting current tobacco use. Using a 0-10 numeric rating 
scale (NRS) to report average level of pain and fatigue, 155 patients re-
ported a mean fatigue score of 4.1 with 47% (n=73) rating their fatigue 
level 5 or higher. The mean pain score for 154 patients was 2.2 with 
21% (n=33) rating their pain level 5 or higher. Anxiety and depression 
were measured by self report in 83 patients. One-third (n=28) reported 
anxiety and 17% (n=14) reported depression triggering a referral 
for psychosocial support. Seventy-four percent of patients (n=166) 
reported having some method of colorectal cancer (CRC) screening 
performed. Eighty-eight percent (114/129) of females reported breast 
cancer screening with mammography and 50% of these (57/114) 
reported mammogram within the last year. Cervical cancer screening 
by Papanicolaou smear (PAP) was reported by 64% of women (82/129) 
with 39% of these women (32/82) having a PAP test within the last 
year. Eighty percent (75/94) of males reported undergoing prostate 
speciﬁc antigen (PSA) testing; 67% (50/75) of these men having PSA 
testing within the past 1 year.
Conclusions: The initial observations of this novel thoracic survivor-
ship program show that a substantial percentage of NSCLC survivors 
report elevated levels of pain, fatigue, anxiety and depression post-
treatment. In addition, adherence to recommended cancer screening 
tests is highly variable. Based on this, interventions to address the 
needs of NSCLC survivors are warranted.
